Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Cell Physiol Biochem ; 33(5): 1369-88, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24853354

RESUMO

Man is water. When life appeared on earth, the primordial cell had a simple structure and could immediately ascertain from the surrounding aquatic environment the substances for nutrition and oxygen, without any need for structural complexity. As part of evolution, during the transition from aquatic to terrestrial life, vertebrates had to fight against dehydration as well as fish in the sea. In this complex mechanism of osmoregulation, the structure and function of some osmoregulatory hormones have been maintained during the evolution of species, from fish to man. Within the homeostatic mechanism, the renin-angiotensin-aldosterone system (RAAS) is crucial in the regulation of renal reasorption of water and sodium. It is also involved in the regulation of renal plasma flux, blood volume and blood pressure. Vasopressin plays a hormonal function in the mechanisms of water homeostasis acting through Aquaporins (AQP), channel-proteins that allow bi-directional water transport across cell membranes.


Assuntos
Aquaporinas/metabolismo , Água/metabolismo , Animais , Homeostase , Humanos , Osmorregulação , Sistema Renina-Angiotensina
2.
Nephrol Dial Transplant ; 29(3): 573-9, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24319014

RESUMO

BACKGROUND: Many authors have investigated the numerous connections between the nervous system and kidneys, and recent literature has indicated that these similar systems are interconnected. Recent scientific works have shown that there is similarity between the cerebral cortex 'viscera representation' and the 'motor omunculus'. We studied the connection between the brain and kidney in vivo using repetitive transcranial magnetic stimulation (rTMS). Proteinuria and albuminuria were used as markers of renal response in patients with diabetes (DP) and in a group of healthy subjects (HSs) who received rTMS for 5 consecutive days. METHODS: The study population consists of the following four groups: Group A (HS stimulated), Group B (HS sham), Group C (DP stimulated) and Group D (DP sham). All subjects in Groups A and C underwent rTMS delivered at a frequency corresponding to 90% of the threshold at rest for 5 consecutive days. All subjects in Groups B and D underwent rTMS delivered with the coil placed on the scalp without delivering electromagnetic stimuli, while another coil at a distance of ∼2 m emitted stimuli at a very low intensity. This strategy ensured that brain stimulation would not occur, so that the subjects felt the vibrations produced by the click of the TMS coil. The proteinuria and albuminuria of 24 h and creatinine clearance were measured at time 0 (T0), after the first session (T1), at the end of the treatment (T5) and 24 h after the last stimulation (Post 24 h). RESULTS: In Group A, there was a statistically significant increase in albuminuria (5.65 ± 0.52 versus 12 ± 0.55 mg/24 h, P = 0.0001) and proteinuria (6.05 ± 0.48 versus 13.1 ± 0.60 mg/24 h, P = 0.0001) at the end of the treatment (T5) compared with the baseline values (T0). In Group C, the albuminuria was statistically higher at T5 than the baseline T0 (416.22 ± 181 versus 677.25 ± 280 mg/24 h, P = 0.04), as was proteinuria (561.37 ± 86 versus 865.125 ± 104 mg/24 h, P = 0.0001); in Group C, the increase in albuminuria (T0 versus post 24 h, P = 0.02) and proteinuria (T0 versus 24 h post, P = 0.0002) persisted at 24 h post. In Groups B and D, statistically significant changes were not found in proteinuria (Group B T0 versus T5, P = 0.61; Group D: T0 versus T5, P = 0.66) and albuminuria (Group B T0 versus T5, P = 0.15; Group D T0 versus T5, P = 0.44) measured at the same times. CONCLUSIONS: Consecutive rTMS is able to induce a statistically significant increase in albuminuria and proteinuria in HS and DP. A functional link between the brain and kidney is possible. For the first time, the results have indicated an increase of proteinuria in subjects undergoing transcranial stimulation.


Assuntos
Diabetes Mellitus/urina , Insuficiência Renal Crônica/terapia , Estimulação Magnética Transcraniana , Adulto , Albuminúria , Encéfalo , Estudos de Casos e Controles , Diabetes Mellitus/terapia , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Renal Crônica/urina , Resultado do Tratamento , Adulto Jovem
3.
J Pers Med ; 14(2)2024 Jan 31.
Artigo em Inglês | MEDLINE | ID: mdl-38392601

RESUMO

PURPOSE: Pneumatosis intestinalis is a radiological finding with incompletely understood pathogenesis. To date, there are no protocols to guide surgical intervention. METHODS: A systematic review of literature, according to PRISMA criteria, was performed. Medline and PubMed were consulted to identify articles reporting on the items "emergency surgery, pneumatosis coli, and pneumatosis intestinalis" from January 2010 up to March 2022. This study has not been registered in relevant databases. RESULTS: A total of 1673 patients were included. The average age was 67.1 ± 17.6 years. The etiology was unknown in 802 (47.9%) patients. Hemodynamic instability (246/1673-14.7% of the patients) was associated with bowel ischemia, necrosis, or perforation (p = 0.019). Conservative management was performed in 824 (49.2%) patients. Surgery was performed 619 (36.9%) times, especially in unstable patients with bowel ischemia signs, lactate levels greater than 2 mmol/L, and PVG (p = 0.0026). In 155 cases, surgery was performed without pathological findings. CONCLUSIONS: Many variables should be considered in the approach to patients with pneumatosis intestinalis. The challenge facing the surgeons is in truly identifying those who really would benefit and need surgical intervention. The watch and wait policy as a first step seems reasonable, reserving surgery only for patients who are unstable or with high suspicion of bowel ischemia, necrosis, or perforation.

4.
Gland Surg ; 12(7): 884-893, 2023 Jul 31.
Artigo em Inglês | MEDLINE | ID: mdl-37727346

RESUMO

Background: According to the latest guidelines, in patients with high-risk nodules with indeterminate cytology, diagnostic lobectomy should be the preferable surgical approach in the absence of factors that suggest a total thyroidectomy. Methods: This retrospective observational study has as its main aim the evaluation of the cases that underwent surgery, for Bethesda class IV nodules in our iodocarent geographical area. Particular attention was paid to carcinoma incidence, preoperative nodule size, histological characteristics of the neoplasm, surgical approach and eventual need of radiometabolic treatment. A total of 320 patients were included that underwent surgery for Bethesda IV nodules, between January 2010 and December 2020, at the General Surgical Clinic of the University Hospital of Parma, Italy. Results: A total of 230 total thyroidectomies (71.9%) and 90 lobectomies (28.1%) were performed. Our data showed a strong impact of the 2015 ATA Guidelines on the surgical approach choice, with a progressive propensity towards a conservative approach and an increase of lobectomies from 7.2% to 41.5% after the new guidelines introduction. However, in our sample the percentage of lobectomies remains below 50%; this data is certainly influenced by the number of cases of multinodular pathology, often bilateral, in our geographical area. The nodules malignancy rate resulted 28.8%. Our data showed that increasing size correlated with an increasing malignancy rate (P<0.01), and follicular carcinomas were found to be larger than papillary carcinomas (P<0.001). A statistically significant correlation also emerged between nodule size increase and local/lymphovascular invasion (P<0.05). On the other hand, there was no statistically significant correlation between nodule size and multifocality, and between nodule size and presence of lymph node metastases. Out of the patients where it was possible to find this data, 66% underwent radioiodiometabolic treatment: 59% with papillary carcinoma, and 85% with follicular carcinoma. Conclusions: In patients with Bethesda IV thyroid nodules, diagnostic lobectomy should be the preferable surgical approach in absence of factors that suggest total thyroidectomy. In our opinion, total thyroidectomy remains the first choice in large nodules (≥4 cm) as these nodules have a high malignancy rate, greater local/lymphovascular invasion and a consequent frequent indication for post-operative radiometabolic treatment.

5.
Nephrol Dial Transplant ; 27(1): 21-7, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22102616

RESUMO

Tubulo-interstitial fibrosis constitutes the final common pathway for all pathological conditions that evolve towards chronic kidney disease, and transforming growth factor-ß1 plays a key role in this process. Furthermore, neutrophil gelatinase-associated lipocalin appears not only to be a simple marker of renal injury but also an active player in disease progression. We are not yet able to control and modulate this phenomenon. Therefore, a better understanding of fibrogenic molecular mechanisms is necessary to detect possible therapeutic strategies that interfere with fibrosis and then stop the progression of renal disease. The line of research called 'regenerative medicine' works toward this. According to many authors, the formation of a fibrotic extracellular matrix disrupts the cells' polarity and stimulates their proliferation, creating conditions for cancer development. However, there is another plausible hypothesis: is it possible that fibrosis provides a sort of 'protection' from the development of a cancer as a consequence of the intense proliferation that characterizes any inflammatory process? In superior organisms, and also in humans, regeneration may have been selected negatively and replaced by fibrosis in the course of evolution, to warrant species survival: in fact, unchecked pluripotent cell production and proliferation can lead to tumour development and the potential death of a single individual. Hence, tumours might be the outcome of the failure of fibrotic processes, most likely due to some mediators predominating over others. So, valid experimental models are necessary to understand the interactions that exist between fibrosis and tumours and to evaluate the real advantage of therapies that aim to inhibit the fibrotic process at the renal level or that of other organs. The ideal approach would be to limit fibrosis and then organ function loss but without exposing the patient to risks of developing a tumour, starting from as early as the drugs prescribed.


Assuntos
Fibrose/patologia , Nefropatias/etiologia , Nefropatias/patologia , Neoplasias/etiologia , Neoplasias/patologia , Animais , Progressão da Doença , Humanos , Regeneração
6.
Blood Purif ; 33(4): 317-23, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22699819

RESUMO

BACKGROUND/AIMS: To evaluate the balance between arginine-vasopressin (AVP) and apelin during hemodialysis and its role in hypotension onset and in the inflammation status. METHODS: We enrolled 50 patients chronically treated with hemodialysis. We assessed plasmatic osmolality, AVP, apelin, mean blood pressure (BP), high-sensitivity C-reactive protein (hsCRP) and ß(2)-microglobulin. RESULTS: Apelin rises during dialytic treatment (from 0.68 ± 0.34 to 1.89 ± 0.56 pg/ml, p < 0.0001), while plasmatic osmolality (from 325 ± 4.54 to 311 ± 1.20 mosm/kg H(2)O, p < 0.0001), AVP (from 4.28 ± 1.12 to 2.48 ± 0.50 pg/ml, p < 0.0001) and mean BP (from 124 ± 6 to 110 ± 7 mm Hg, p < 0.0001) decrease. At multivariate regression with respect to apelin, only mean BP remains (r = -0.95, p < 0.0001). We also correlated the AVP/apelin ratio with BP. Moreover, apelin is inversely related to hsCRP (r = -0.79, p < 0.0001). CONCLUSIONS: The AVP/apelin balance changes with plasmatic osmolality variations induced by hemodialytic sessions and could represent a physiopathological marker of arterial hypo- and hypertension. Finally, apelin appears inversely related to inflammation markers.


Assuntos
Arginina Vasopressina/sangue , Hipotensão/sangue , Hipotensão/etiologia , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Diálise Renal/efeitos adversos , Idoso , Apelina , Pressão Sanguínea , Proteína C-Reativa/análise , Estudos de Coortes , Feminino , Humanos , Inflamação/sangue , Masculino , Pessoa de Meia-Idade , Concentração Osmolar , Plasma/química , Microglobulina beta-2/sangue
7.
Ren Fail ; 34(6): 818-20, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22462470

RESUMO

Uremic patients are characterized by a "pro-arrhythmic substrate." Arrhythmia appearance during hemodialysis (HD) is an unexpected event with a high incidence of mortality and morbidity and difficult to record in patients repeatedly checked using electrocardiogram (ECG). Furthermore the carrying out of this important examination by classical devices during HD is uncomfortable and sometimes stressful for the patient. It may be very useful to monitor the patient's cardiac activity during the whole HD session. We tried to overcome these difficulties using Whealthy(®) (Wearable Health Care System), a wearable system in a T-shirt composed of conductors and piezoresistive materials, integrated to form fibers and threads connected to tissular sensors, electrodes, and connectors. ECG and pneumographic impedance signals are acquired by the electrodes in the tissue, and the data are registered by a small computer and transmitted via GPRS or Bluetooth.


Assuntos
Doenças Cardiovasculares/diagnóstico , Vestuário , Eletrocardiografia , Monitorização Fisiológica/instrumentação , Diálise Renal , Humanos
8.
Ren Fail ; 34(4): 495-8, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22260509

RESUMO

Joubert syndrome (JBTS) is a rare autosomal recessive disorder with an underestimated prevalence due to lack of recognition of clinical signs or failure to diagnose this pathology. JBTS is clinically heterogeneous, and it is characterized by a multiple organ involvement predominantly due to the requirement for Joubert gene function in several tissues. Renal disease affects approximately 30% of patients with JBTS, presenting itself in most cases as nephronophthisis (NPHP), a structural tubulo-interstitial disorder characterized by thickened basal membrane of the tubular epithelium and progressive interstitial fibrosis, associated with cysts at the cortico-medullary junction. We propose three cases concerning three patients with JBTS having different years of illness and degrees of renal impairment, evaluating the parameters of renal function at the time of genetic diagnosis and seen after a follow-up of 7 years. We measured neutrophil gelatinase-associated lipocalin (NGAL), considered as an excellent predictor of kidney injury, to evaluate whether this biomarker might be an early biomarker for JBTS-related kidney disease. NGAL was high in all three cases, but with different levels, indicating a tubular suffering typical of this syndrome, with dissimilar severity in the analyzed subjects. NGAL could represent an early indicator of renal damage useful to start an intensive nephrologic follow-up.


Assuntos
Biomarcadores/sangue , Doenças Cerebelares/sangue , Diagnóstico Precoce , Anormalidades do Olho/sangue , Doenças Renais Císticas/sangue , Falência Renal Crônica/sangue , Lipocalinas/sangue , Proteínas Proto-Oncogênicas/sangue , Anormalidades Múltiplas , Proteínas de Fase Aguda , Adolescente , Doenças Cerebelares/complicações , Doenças Cerebelares/diagnóstico , Cerebelo/anormalidades , Diagnóstico Diferencial , Anormalidades do Olho/complicações , Anormalidades do Olho/diagnóstico , Feminino , Seguimentos , Humanos , Doenças Renais Císticas/complicações , Doenças Renais Císticas/diagnóstico , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/etiologia , Lipocalina-2 , Imageamento por Ressonância Magnética , Masculino , Retina/anormalidades , Adulto Jovem
9.
Kidney Blood Press Res ; 34(2): 104-10, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21282963

RESUMO

BACKGROUND: Obestatin plays a key role in the process of energy balance maintenance with an anorectic effect. The main aim of the study was to evaluate obestatin in uremic patients to determine whether it is correlated with nutritional and inflammatory status. METHODS: We studied plasma obestatin in uremic patients (n = 50) undergoing hemodialysis therapy and in healthy subjects. Plasma obestatin was measured using an ELISA kit. RESULTS: Obestatin levels in uremic patients were lower than in healthy subjects (p < 0.0001). Patients with a body mass index (BMI) >23 had lower obestatin levels than those with a BMI <23 (p = 0.001). After multivariate analysis, direct correlations were maintained between obestatin and high-sensitivity C-reactive protein (ß = 0.68, p < 0.0001) and total alkaline phosphatases (ß = 0.30, p = 0.03), while inverse correlations were found with iron (ß = -0.32, p = 0.002) and calcium-phosphorous product (ß = -0.40, p = 0.001). CONCLUSIONS: Based on the present observational data, obestatin might be implicated in the inflammatory state and the disturbances of calcium/phosphate metabolism of hemodialysis patients. However, further studies are warranted to determine whether this hormone plays a key role in contributing to malnutrition and to the chronic inflammatory process.


Assuntos
Grelina/sangue , Inflamação/induzido quimicamente , Minerais/metabolismo , Diálise Renal , Idoso , Índice de Massa Corporal , Cálcio/sangue , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Desnutrição/induzido quimicamente , Pessoa de Meia-Idade , Minerais/sangue , Estado Nutricional , Fosfatos/sangue , Uremia/sangue , Uremia/terapia
10.
Ann Nutr Metab ; 59(2-4): 193-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22156552

RESUMO

Obestatin is a 23-amino acid peptide hormone released from the stomach and is present not only in the gastrointestinal tract, but also in the spleen, mammary gland, breast milk and plasma. Obestatin appears to function as part of a complex gut-brain network whereby hormones and substances from the stomach and intestines signal the brain about satiety or hunger. In contrast to ghrelin, which causes hyperphagia and obesity, obestatin appears to act as an anorectic hormone, decreasing food intake and reducing body weight gain. Further studies have shown that obestatin is also involved in improving memory, regulating sleep, affecting cell proliferation, increasing the secretion of pancreatic juice enzymes and inhibiting glucose-induced insulin secretion. This hormone has not only been studied in the field of physiology but also in the fields of obesity and diabetes mellitus, and in patients with psychogenic eating disorders. Obestatin has a role in regulating the cell cycle by exerting proliferative effects that may be seen in cell physiology and oncology. Given the current controversy regarding the effects of obestatin and its cognate ligand, this article provides the latest review of the physiological and pathological characteristics of this hormone.


Assuntos
Hormônios Gastrointestinais/fisiologia , Grelina/fisiologia , Animais , Anorexia/metabolismo , Aterosclerose/metabolismo , Glicemia , Proliferação de Células , Diabetes Mellitus/metabolismo , Ingestão de Energia , Metabolismo Energético , Alimentos , Hormônios Gastrointestinais/metabolismo , Trato Gastrointestinal/metabolismo , Grelina/metabolismo , Humanos , Insulina/metabolismo , Secreção de Insulina , Modelos Animais , Obesidade/metabolismo , Receptores de Grelina/metabolismo
11.
Kidney Blood Press Res ; 33(2): 100-10, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20357496

RESUMO

Nephropathic subjects show an increased tendency to develop cardiovascular diseases, mainly as the consequence of several risk factors including increased oxidative stress, inflammation, physical inactivity, anemia, vascular calcification, and endothelial dysfunction. The alterations in lipid metabolism represent a relatively lesser important cause of genesis and progression of atherosclerosis. Unfortunately, in these patients the atherogenic potential of dyslipidemia may depend more on apolipoproteins than on lipid abnormalities, and may not always be recognized by measurement of plasma lipids alone. The aim of this review was therefore to analyze the main lipid alterations that can occur in nephropathic patients, as well as their causes and their effects on the cardiovascular system. The clinical evidence and recommendations for the use of lipid-regulating drugs in patients with chronic kidney disease, nephrotic syndrome, in patients undergoing hemo- and peritoneal dialysis and in transplanted patients was also reviewed. Moreover, we analyzed the link between dyslipidemia and kidney disease onset and progression and the role of statins in preventing it.


Assuntos
Dislipidemias/etiologia , Nefropatias/metabolismo , Metabolismo dos Lipídeos , Aterosclerose/etiologia , Doença Crônica , Dislipidemias/complicações , Humanos , Nefropatias/complicações , Nefropatias/diagnóstico , Nefropatias/terapia
12.
Med Sci Monit ; 16(6): RA131-5, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20512104

RESUMO

Neutrophil Gelatinase-Associated Lipocalin (NGAL), a small 25-kD peptide, originally discovered as an antibacterial factor of natural immunity and an acute-phase protein, represents a key factor in the regulation of erythrocyte growth due to its ability to inhibit the maturation and differentiation of bone marrow erythroid precursors. When a condition of primary anemia occurs, the body has a double response with respect to NGAL production and its systemic effects. Because NGAL is a protective, anti-oxidant factor, there is an increase in the peripheral production of the protein in order to counteract hypoxic stress. However, the increased systemic NGAL levels would have a negative impact on the bone marrow red cell homeostasis, thus the bone marrow counteracts this potential negative effect by reducing the production of NGAL by the same erythroid precursor and by enhancing the survival mechanisms of these cells. Several systemic diseases associated with the presence of secondary anemia, such as chronic renal failure, chronic inflammation and cancer, are known to induce a dramatic increase in circulating NGAL levels. This may represent a further, important cause of the development and worsening of anemia itself. From this point of view, NGAL may thus become an alternative therapeutic target for improving the treatment of secondary anemia related to these conditions.


Assuntos
Proteínas de Fase Aguda/fisiologia , Anemia/metabolismo , Lipocalinas/fisiologia , Proteínas Proto-Oncogênicas/fisiologia , Proteínas de Fase Aguda/metabolismo , Animais , Antioxidantes/metabolismo , Apoptose , Eritrócitos/metabolismo , Humanos , Hipóxia , Inflamação , Falência Renal Crônica/metabolismo , Lipocalina-2 , Lipocalinas/metabolismo , Camundongos , Modelos Biológicos , Neoplasias/metabolismo , Estresse Oxidativo , Proteínas Proto-Oncogênicas/metabolismo , Espécies Reativas de Oxigênio , Proteínas Recombinantes/metabolismo
13.
G Ital Nefrol ; 27(6): 609-15, 2010.
Artigo em Italiano | MEDLINE | ID: mdl-21132643

RESUMO

Erythropoietin synthesis is one of the essential adaptive responses to a hypoxic environment. In mammals, a renal oxygen sensor capable of stimulating erythropoietic hormone synthesis through a transcriptional factor called HIF (hypoxia-inducible factor) has long been identified. Recent research has demonstrated that cerebral astrocytes and skin keratocytes can also produce erythropoietin as a response to different oxygen concentrations. Therefore, it is possible to hypothesize a skin-brain-kidney link which, through erythropoietin production, modulates the oxygen contribution to tissues. Moreover, the results are not so unambiguous and further research on the pleiotropic effects of erythropoetin would be opportune.


Assuntos
Astrócitos/metabolismo , Córtex Cerebral/metabolismo , Eritropoetina/metabolismo , Fator 1 Induzível por Hipóxia/metabolismo , Rim/metabolismo , Oxigênio/metabolismo , Pele/metabolismo , Animais , Eritropoese/genética , Eritropoetina/biossíntese , Eritropoetina/genética , Medicina Baseada em Evidências , Humanos , Hipóxia/metabolismo , Fator 1 Induzível por Hipóxia/genética , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Queratinócitos/metabolismo , Proteínas Recombinantes
14.
Recenti Prog Med ; 101(6): 253-67, 2010 Jun.
Artigo em Italiano | MEDLINE | ID: mdl-20672574

RESUMO

The erythropoietin is produced by the kidney and other organs. EPO does not only affect erythroid cells, but also other blood cell lines, such as myeloid cells, lymphocytes and megakaryocytes. This hormone can also enhance phagocytes function of the polymorph nuclear cells and reduces the activation of macrophages, thus modulating the inflammatory process. Hematopoietic and endothelial cells probably have the same cellular origin, and the discovery of erythropoietin receptors also on mesangial and myocardial cells and smooth muscle fibro-cells has prompted the study of the pleiotropic actions of this hormone. Through its receptors, spread out over the body, it carries out many actions which range from the erythrogenesis after hypoxic stimuli to the tissue protection of the heart and the brain after ischemia. Erythropoietin also acts in the endothelial proliferation of new vessels involving the tumor genesis, but it opens new frontiers to the employment of rHuEPO in the Regenerative Medicine.


Assuntos
Eritropoetina/fisiologia , Anemia/tratamento farmacológico , Anemia/fisiopatologia , Animais , Encéfalo/metabolismo , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/prevenção & controle , Endotélio Vascular/fisiologia , Células Eritroides/citologia , Eritropoese/fisiologia , Eritropoetina/uso terapêutico , Regulação da Expressão Gênica/fisiologia , Humanos , Hipóxia/fisiopatologia , Isquemia/fisiopatologia , Rim/metabolismo , Camundongos , Modelos Biológicos , Células Mieloides/citologia , Miocárdio/metabolismo , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/fisiopatologia , Neovascularização Fisiológica , Especificidade de Órgãos , Oxigênio/fisiologia , Receptores da Eritropoetina/efeitos dos fármacos , Receptores da Eritropoetina/fisiologia
15.
Kidney Blood Press Res ; 32(2): 91-8, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19321980

RESUMO

BACKGROUND/AIMS: Renal tubulointerstitium plays an important role in the development and progression of diabetic nephropathy. METHODS: With the present study, we aimed at evaluating the levels of neutrophil gelatinase-associated lipocalin (NGAL), a tubular stress protein, in serum (sNGAL) and urine (uNGAL) from a cohort of 56 patients with type 2 diabetes mellitus categorized into three groups (normoalbuminuria, microalbuminuria and diabetic nephropathy). RESULTS: All groups showed increased NGAL values with respect to controls; interestingly, increased NGAL levels were already found in diabetic patients without early signs of glomerular damage (normoalbuminuric). Both sNGAL and uNGAL increased in parallel with the severity of renal disease, reaching higher levels in patients with manifest diabetic nephropathy. The assessment of Pearson coefficient evidenced significant relationships between sNGAL and, respectively, uNGAL, serum creatinine and GFR (inversely) and between uNGAL and, respectively, serum creatinine, proteinuria, albuminuria, serum albumin and GFR (both inversely). CONCLUSIONS: NGAL might play an important role in the pathophysiology of renal adaptation to diabetes, probably as a defensive mechanism aiming to mitigate tubular suffering. Furthermore, NGAL measurement might become a useful and noninvasive tool for the evaluation of renal involvement in diabetic patients as well as for the early diagnosis of incipient nephropathy.


Assuntos
Proteínas de Fase Aguda/urina , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/urina , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/urina , Lipocalinas/sangue , Lipocalinas/urina , Proteínas Proto-Oncogênicas/sangue , Proteínas Proto-Oncogênicas/urina , Adulto , Biomarcadores/sangue , Biomarcadores/urina , Estudos de Coortes , Diabetes Mellitus Tipo 2/diagnóstico , Nefropatias Diabéticas/diagnóstico , Feminino , Humanos , Túbulos Renais/química , Túbulos Renais/metabolismo , Lipocalina-2 , Masculino , Pessoa de Meia-Idade , Fatores de Tempo
16.
Ren Fail ; 31(3): 239-45, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19288330

RESUMO

Approximately one-third of all dialysis patients have mild to moderate malnutrition, while 6-8% have severe malnutrition, which is associated with increased morbidity and mortality rates and numerous pre-existing factors directly correlated with, or existing prior to, replacement hemodialysis. However, moderate to severe malnutrition (present in 10-30% of dialysis patients) is a prevalent cause of death among the elderly. Many of these patients have a particularly unstable cardiovascular and metabolic status that, independent of any underlying uremia and/or dialysis, impacts negatively on both their quality of life and clinical status. Moreover, their condition is often further exacerbated by dialysis itself, with its acute (e.g., hypotension and sensorial alterations) and chronic complications, including an exacerbation of malnutrition and systemic vascular disease. Malnutrition can occur secondary not only to erroneous dietary choices or uremia, but it may also depend on the patient's level of tolerance to dialysis and on the dialysis modality. Despite the improvements made to dialysis techniques, the nutritional condition of elderly patients on dialysis for chronic renal failure remains a cause for concern. In this patient category, it is therefore mandatory to ensure the daily supervision of nutritional status and early control when the first signs of malnutrition appear.


Assuntos
Falência Renal Crônica/terapia , Desnutrição , Diálise Renal/efeitos adversos , Uremia/terapia , Absorciometria de Fóton , Idoso , Idoso de 80 Anos ou mais , Carnitina/administração & dosagem , Comorbidade , Suplementos Nutricionais , Humanos , Falência Renal Crônica/complicações , Desnutrição/diagnóstico , Desnutrição/epidemiologia , Desnutrição/etiologia , Desnutrição/mortalidade , Desnutrição/terapia , Avaliação Nutricional , Diálise Peritoneal/efeitos adversos , Desnutrição Proteico-Calórica/diagnóstico , Desnutrição Proteico-Calórica/epidemiologia , Desnutrição Proteico-Calórica/etiologia , Desnutrição Proteico-Calórica/mortalidade , Desnutrição Proteico-Calórica/terapia , Qualidade de Vida , Índice de Gravidade de Doença , Taxa de Sobrevida , Uremia/complicações , Complexo Vitamínico B/administração & dosagem
17.
Am J Kidney Dis ; 52(3): 595-605, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18725016

RESUMO

Neutrophil gelatinase-associated lipocalin (NGAL) is a protein belonging to the lipocalin superfamily initially found in activated neutrophils, in accordance with its role as an innate antibacterial factor. However, it subsequently was shown that many other types of cells, including in the kidney tubule, may produce NGAL in response to various injuries. The increase in NGAL production and release from tubular cells after harmful stimuli of various kinds may have self-defensive intent based on the activation of specific iron-dependent pathways, which in all probability also represent the mechanism through which NGAL promotes kidney growth and differentiation. NGAL levels predict the future appearance of acute kidney injury after treatments potentially detrimental to the kidney and even the acute worsening of unstable nephropathies. Furthermore, recent evidence also suggests that NGAL somehow may be involved in the pathophysiological process of chronic renal diseases, such as polycystic kidney disease and glomerulonephritis. NGAL levels clearly correlate with severity of renal impairment, probably expressing the degree of active damage underlying the chronic condition. For all these reasons, NGAL may become one of the most promising next-generation biomarkers in clinical nephrology and beyond.


Assuntos
Proteínas de Fase Aguda/metabolismo , Nefropatias/metabolismo , Lipocalinas/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Doença Aguda , Proteínas de Fase Aguda/urina , Biomarcadores/sangue , Biomarcadores/metabolismo , Biomarcadores/urina , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Doença Crônica , Humanos , Rim/crescimento & desenvolvimento , Rim/metabolismo , Nefropatias/sangue , Nefropatias/etiologia , Nefropatias/urina , Lipocalina-2 , Lipocalinas/sangue , Lipocalinas/urina , Valor Preditivo dos Testes , Proteínas Proto-Oncogênicas/sangue , Proteínas Proto-Oncogênicas/urina
18.
Kidney Blood Press Res ; 31(5): 330-6, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18936550

RESUMO

In developed countries, the incidence of end-stage renal failure is constantly increasing, and uremia will soon be a disease typically found in mature and elderly adults. Almost invariably, the physical condition of the elderly patient with terminal uremia is extremely poor, and therapeutic approach complex. Frequent co-morbidity, treatment with many different drugs, the high risk of iatrogenic damage, advanced age and socio-environmental conditions further complicate the management of these patients. While replacement therapy may become necessary, peritoneal dialysis may have advantages over hemodialysis. Peritoneal dialysis causes less hemodynamic stress, does not necessitate vascular access and allows mobility, although it incurs a high incidence of peritonitis and vascular disease. Where hemodialysis is the only feasible treatment, procedures used for vascular access are frequently followed by several complications, representing an important cause of morbidity and hospitalization. In addition, even if it may improve the patient's quality of life, vascular condition, intradialytic hypotension, heart disease, intestinal bleeding and amyloidotic arthropathy are critical aspects of dialysis in the elderly patient. Therefore, particular attention from clinicians and administrators is required and the best possible strategies must be identified in order to provide effective and appropriate services to address these special patients' needs.


Assuntos
Diálise Renal , Idoso , Idoso de 80 Anos ou mais , Gerenciamento Clínico , Humanos , Diálise Peritoneal/efeitos adversos , Diálise Renal/efeitos adversos , Uremia/complicações , Uremia/terapia
19.
Artigo em Inglês | MEDLINE | ID: mdl-29571117

RESUMO

This paper reports a novel fabric phase sorptive extraction-high performance liquid chromatography-photodiode array detection (FPSE-HPLC-PDA) method for the simultaneous extraction and analysis of three drug residues (ciprofloxacin, sulfasalazine, and cortisone) in human whole blood, plasma, and urine samples, generally administered in human patients to treat inflammatory bowel disease (IBD). The drugs of interest were well resolved using a Luna C18 column (250 mm × 4.6 mm; 5 µm particle size) in gradient elution mode within 20 min. The analytical method was optimized and validated in the range 0.05-10 µg/mL for whole blood, 0.25-10 µg/mL for human plasma, and 0.10-10 µg/mL for human urine. Blank human whole blood, plasma, and urine were used as the sample matrix for the method development and validation; while methyl-p-hydroxybenzoate was used as the internal standard (IS). Weighted-matrix matched standard calibration curves showed a good linearity up to a concentration of 10 µg/mL. The intra- and inter-day accuracy values (precision and trueness) were found in the range from -10.9% to 12.3%, and the performances of the validated FPSE-HPLC-PDA were further tested on real IBD patient samples. This is the first FPSE procedure applied simultaneously to whole blood, plasma, and urine samples for the determination of residual IBD drugs, which possess a wide range of polarity (logP values ranging from 2.30 for Ciprofloxacin, to 1.66 for Cortisone, and 2.92 for Sulfasalazine). The new approach exhibits high potential for immediate adoptation as a rapid, robust and green analytical tool for future clinical and pharmaceutical applications.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Fármacos Gastrointestinais/análise , Doenças Inflamatórias Intestinais/tratamento farmacológico , Adsorção , Feminino , Fármacos Gastrointestinais/uso terapêutico , Humanos , Limite de Detecção , Modelos Lineares , Extração Líquido-Líquido , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes
20.
Clin Exp Med ; 15(1): 97-105, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24469934

RESUMO

Apelin regulates angiogenesis, stimulating endothelial cell proliferation and migration. It is upregulated during tumor angiogenesis, and its overexpression was reported to increase tumor growth. Furthermore, apelin controls vasopressin release and body fluid homeostasis. The aim of this study was to examine the correlations between apelin expression and clinical outcomes in oncologic patients, such as cancer disease progression and patient's survival. Apelin levels were evaluated in a cohort of 95 patients affected by different varieties of cancer. Partial remission and stable disease were assigned to the 'no progression' group, comparing it with the progressor group. Patients were followed up for 2 years. Receiver operating characteristics analysis was employed for identifying the progression of the oncologic disease and Kaplan-Meier curves assessed the survival. Adjusted risk estimates for progression endpoint were calculated using Cox proportional hazard regression analysis. Oncologic patients had higher apelin levels compared with healthy subjects, and apelin was closely related to the stages of the disease. In the hyponatremia group, apelin values were significantly higher than patients with eunatremia. After the follow-up of 24 months, 41 patients (43%) reached the endpoint. Progressor subjects presented significantly increased apelin values at baseline compared with non-progressor. Univariate followed by multivariate Cox proportional hazard regression analysis showed that apelin predicted cancer progression independently of other potential confounders. In patients with cancer, apelin closely reflects the stage of the disease and represents a strong and independent risk marker for cancer progression.


Assuntos
Biomarcadores Tumorais/genética , Hiponatremia/diagnóstico , Peptídeos e Proteínas de Sinalização Intercelular/genética , Neoplasias/diagnóstico , Insuficiência Renal/diagnóstico , Idoso , Apelina , Progressão da Doença , Feminino , Seguimentos , Expressão Gênica , Humanos , Hiponatremia/complicações , Hiponatremia/genética , Hiponatremia/mortalidade , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Neoplasias/complicações , Neoplasias/genética , Neoplasias/mortalidade , Prognóstico , Modelos de Riscos Proporcionais , Curva ROC , Insuficiência Renal/complicações , Insuficiência Renal/genética , Insuficiência Renal/mortalidade , Risco , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA